Drug Profile
Research programme: lipocalin derivatives - Pieris Pharmaceuticals/Daiichi Sankyo
Latest Information Update: 07 Jun 2019
Price :
$50
*
At a glance
- Originator Pieris
- Developer Pieris Pharmaceuticals
- Class Recombinant proteins
- Mechanism of Action Calcitonin gene-related peptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified